Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.202,69
0,50%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ KalVista Pharmaceuticals Inc (KALV) KalVista Pharmaceuticals Inc (KALV) Notizie

KalVista Pharmaceuticals Inc

KALV
12,13
-0,04 (-0,33%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
01/5/202412:30BWKalVista Pharmaceuticals Highlights Strategic Plans for..
22/4/202412:30BWKalVista Pharmaceuticals Appoints William C. Fairey to Board..
03/4/202412:30BWKalVista Pharmaceuticals to Present at 23rd Annual Needham..
02/4/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
18/3/202411:30BWKalVista Pharmaceuticals Presents Real-World Data on Burden..
12/3/202411:30BWKalVista Pharmaceuticals Awarded UK Promising Innovative..
11/3/202421:37EDGAR2Form 8-K - Current report
11/3/202421:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/3/202411:30BWKalVista Pharmaceuticals Reports Third Fiscal Quarter..
08/3/202422:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202412:30BWKalVista Pharmaceuticals to Present HAE Attack Journey Data..
07/3/202412:38EDGAR2Form 8-K - Current report
07/3/202412:30BWKalVista Pharmaceuticals Announces Appointment of Benjamin..
06/3/202412:30BWKalVista Pharmaceuticals to Participate in the Leerink..
04/3/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
27/2/202412:30BWKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE..
26/2/202412:30BWKalVista Pharmaceuticals Presents Additional Phase 3..
22/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202419:22EDGAR2Form SC 13D/A - General statement of acquisition of..
22/2/202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202403:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:49EDGAR2Form SC 13D/A - General statement of acquisition of..
20/2/202412:30BWKalVista Pharmaceuticals Awarded UK Innovation Passport for..
16/2/202422:32EDGAR2Form 8-K - Current report
16/2/202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202412:30BWKalVista Pharmaceuticals to Present Phase 3 Sebetralstat..
15/2/202412:30BWKalVista Pharmaceuticals Announces Pricing of a $160.1..
15/2/202402:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202423:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202422:18BWKalVista Pharmaceuticals Announces Proposed Public Offering..
14/2/202422:14EDGAR2Form 8-K - Current report
13/2/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202412:55EDGAR2Form 8-K - Current report
13/2/202412:30BWKalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial..
13/2/202402:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/2/202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202412:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
Apertura: 12,24 Min: 11,955 Max: 12,48
Chiusura: 12,17

La tua Cronologia

NASDAQ
KALV
KalVista Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network